Intra-Cellular Therapies ITCI 深 沪
已收盘 04-02 16:00:00 美东时间
131.87
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 131.87
- 总市值 1411.01万
- 52周最高 131.98
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 64.09
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 131.98
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.75
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多146 亿美元收购！强生重磅新药 III 期成功
（来源：求实药社） 当地时间 9 月 21 日，强生宣布CAPLYTA（卢美哌隆）治疗伴或不伴混合特征的I 型双相情感障碍成人躁狂发作的...
09-23 12:02
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
CAPLYTA® significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3 Results build on th...
09-21 20:00
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
LB Pharmaceuticals Inc announced the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer. Dr. Kozauer brings over two decades of experience in neuropsychiatric drug development, including schizophrenia, mood disorders, and neurodegenerative diseases. She previously led clinical development at Intra-Cellular Therapies and Centessa Pharmaceuticals. LB Pharmaceuticals is advancing its Phase 3 NOVA-2 trial for LB-102, a potential first be...
09-15 12:00
Cybin reports Q1 results
Cybin press release (HELP): Q1 Net loss was $47.8 million for the quarter ended June 30, 2026, compared to a net loss of $24.6 million in the same period last year. Cash totaled $166.4 million as of J...
08-14 19:31
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Helus Pharma appointed Michael Halstead as CEO and reported progress in its clinical programs, including completion of enrollment in the Phase 3 APPROACH study for HLP003 in MDD, positive DDI results, and advancement of HLP004 for GAD. The company also completed a $50 million offering, strengthening its balance sheet. Financial highlights include $166.4 million in cash as of June 30, 2026, and a net loss of $47.8 million for the quarter.
08-14 11:28
解码致病通路 加快研发突破
（来源：中国医药报） 转自：中国医药报 近年来，与中枢神经系统（CNS）疾病相关的全球疾病负担持续上升，造成巨大的经济影响。预计到2030年，仅心理健康问题造...
08-06 07:59
Helus Pharma names ex-Intra-Cellular executive Michael Halstead as CEO
Helus Pharma (HELP) has appointed Michael Halstead as chief executive officer, effective immediately. Halstead previously served as president of Intra-Cellular Therapies, where he helped scale the com...
08-03 19:59
百亿美金并购新狂潮背后
原标题：百亿美金并购新狂潮背后 又一笔百亿美元级并购诞生。 7月6日，Vertex宣布以每股85美元、总价约100亿美元的全现金交易，正式将专注于内分泌罕见病...
07-08 10:19
